Compare GNT & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNT | FATE |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.7M | 125.6M |
| IPO Year | N/A | 2013 |
| Metric | GNT | FATE |
|---|---|---|
| Price | $8.81 | $2.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 96.7K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.43 | $0.92 |
| 52 Week High | $9.30 | $3.23 |
| Indicator | GNT | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 73.95 | 56.93 |
| Support Level | $7.81 | $1.01 |
| Resistance Level | $9.26 | $2.88 |
| Average True Range (ATR) | 0.13 | 0.19 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 97.83 | 81.75 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.